Abarceo Pharma
  • About
    • Board Members
  • Team
  • Science
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page

VDAC1 identified as a novel target in Type 2 diabetes

by SD-AbarceoPharma | Oct 4, 2018 | Diabetes, VDAC1

Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi, world-class experts in beta cell biology, discovered that hyperglycemia increases VDAC1 expression and is mistargeted to the beta cell surface in Type 2 diabetes patients. Read...

Recent Posts

  • Rapidus: Diabetes companies collect SEK 21.5 million (article in Swedish)
  • Almi Invest investerar i Abarceos nya diabetesbehandling
  • VDAC1 identified as a novel target in Type 2 diabetes

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2022 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy

    Cleantalk Pixel